Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature
-
Abdulsamet Erden
,
Levent Kılıç
Abstract
Background:
Relapsing polychondritis (RP) is a rare autoimmune disorder, and myelodysplastic syndrome (MDS) is accompanied by RP at variable rates. Herein, we report a case with RP and MDS who responded dramatically to 5-azacitidine for MDS.
Case presentation:
With conventional immunosuppressive treatment, our patient had several episodes of different side effects, including infections. With the diagnosis of MDS and initiation of azacitidine treatment, all the manifestations of RP disappeared, and remission was achieved for MDS. Although he had relapses of either RP or MDS after several years of azacitidine treatment, all relapses were controlled well with the initiation of azacitidine treatment every time.
Conclusions:
Azacitidine should be kept in mind as a treatment option for RP patients with MDS.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Okamoto T, Okada M, Mori A, Takatsuka H, Wada H, Tamura A, et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 1997;66:345–51.10.1016/S0925-5710(97)00042-XSuche in Google Scholar
2. Chang SJ, Lu CC, Chung YM, Lee SS, Chou CT, Huang DF. Laryngotracheal involvement as the initial manifestation of relapsing polychondritis. J Chin Med Assoc 2005;68:279–82.10.1016/S1726-4901(09)70151-0Suche in Google Scholar
3. McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976;55:193–215.10.1097/00005792-197605000-00001Suche in Google Scholar
4. Fozza C, Longinotti M. The role of T-cells in the pathogenesis of myelodysplastic syndromes: passengers and drivers. Leuk Res 2013;37:201–3.10.1016/j.leukres.2012.11.007Suche in Google Scholar
5. de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Levesque H, et al. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken) 2011;63:1188–94.10.1002/acr.20504Suche in Google Scholar
6. Fozza C, Crobu V, Isoni MA, Dore F. The immune landscape of myelodysplastic syndromes. Crit Rev Oncol Hematol 2016;107:90–9.10.1016/j.critrevonc.2016.08.016Suche in Google Scholar
7. Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford) 2016;55:291–300.10.1093/rheumatology/kev294Suche in Google Scholar
8. Hebbar M, Hebbar-Savéan K, Fenaux P. Maladies systémiques au cours des syndromes myélodysplasiques. Rev Med Interne 1995;16:897–904.10.1016/0248-8663(96)80810-1Suche in Google Scholar
9. Piette JC, Papo T, Chavanon P, Houng DL, Frances C, Godeau P. Myelodysplasia and relapsing polychondritis. J Rheumatol 1995;22:1208–9.Suche in Google Scholar
10. Frances C, el Rassi R, Laporte JL, Rybojad M, Papo T, Piette JC. Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center. Medicine (Baltimore) 2001;80:173–9.10.1097/00005792-200105000-00003Suche in Google Scholar PubMed
11. Anderson L, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100:822–8.10.1038/sj.bjc.6604935Suche in Google Scholar PubMed PubMed Central
12. Kristinsson SY, Björkholm M, Hultcrantz M, Derolf ÅR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011;29:2897–903.10.1200/JCO.2011.34.8540Suche in Google Scholar PubMed PubMed Central
13. Wilson AB, Neogi T, Prout M, Jick S. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the general practice research database. Cancer Epidemiol 2014;38:544–9.10.1016/j.canep.2014.08.003Suche in Google Scholar PubMed
14. Silverman RS. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 2001;6(suppl 5):8–14.10.1634/theoncologist.6-suppl_5-8Suche in Google Scholar PubMed
15. Fraison JB, Makinian A, Gringnano E, Kahn JE, Arlet JB, Dexaux O, et al. Efficacy of azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res 2016;43:13–7.10.1016/j.leukres.2016.02.005Suche in Google Scholar PubMed
16. Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, Bontkes HJ. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 2011;153:568–81.10.1111/j.1365-2141.2011.08683.xSuche in Google Scholar PubMed
17. Michet CJ Jr, McKenna CH, Luthra HS, O’Fallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med 1986;104:74–78.10.7326/0003-4819-104-1-74Suche in Google Scholar PubMed
©2018 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Editorial
- New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics
- Original Articles
- Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies
- Correlation between plasma concentrations of tramadol and its metabolites and the incidence of seizure in tramadol-intoxicated patients
- Effect of the African-specific promoter polymorphisms on the SLC22A2 gene expression levels
- Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)
- Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS score
- Case Report
- Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature
Artikel in diesem Heft
- Frontmatter
- Editorial
- New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics
- Original Articles
- Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies
- Correlation between plasma concentrations of tramadol and its metabolites and the incidence of seizure in tramadol-intoxicated patients
- Effect of the African-specific promoter polymorphisms on the SLC22A2 gene expression levels
- Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)
- Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS score
- Case Report
- Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature
